300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Construction
Mobile
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Real Estate
Publishing
Wine and Spirits
Sporting Goods
Mobile Apps
Finance
Manufacturing
Music
FinTech
Social Media
Franchise
Internet
Art
Mobile Advertising
Android
Enterprise
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Sudan
Norway
Malawi
Isle of Man
Haiti
Iran
Madagascar
Lesotho
Nepal
Russian Federation
Pakistan
Turkey
Liberia
Mexico
Tajikistan
Romania
Sweden
Zambia
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Côte d'Ivoire
Kuwait
Czech Republic
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
New Zealand
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Botswana
Seychelles
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Sierra Leone
Philippines
El Salvador
Portugal
Senegal
India
Canada
Germany
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
United States
Tanzania
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Bangladesh
Cyprus
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
S-Venture Capital Dortmund, VC Fund

S-Venture Capital Dortmund

VC Fund

Deutsch, Germany

S-Venture Capital Dortmund is a VC fund in Deutsch focused on Biotechnology and Guides. S-Venture Capital Dortmund aims to fund technology companies and is a German regional investment group.

Total investments:
9
Last investment:
Lead investor:
0%

Last updated:

Industries S-Venture Capital Dortmund invests in

BiotechnologyGuidesGeneticsSoftwareManufacturing

Stages S-Venture Capital Dortmund invests in

Series BFunding RoundSeries ASeries C

Countries S-Venture Capital Dortmund invests in

Germany

Round sizes

Series B $3.6M–$9M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series B
$3.6M–$9M

Investment Focus

Industry

  • Biotechnology 2 (22%)
  • Guides 1 (11%)
  • Genetics 1 (11%)
  • Software 1 (11%)
  • Manufacturing 1 (11%)
See all 9 industries →

Stage

  • Series B 2 (22%)
  • Funding Round 2 (22%)
  • Series A 1 (11%)
  • Series C 1 (11%)

Team

NameTitleInvestmentsLinksEmail
CEO Total investments: 0 Find email
Director Total investments: 0 Find email

Investments

CompanyDescriptionRoundLinks
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others. $12.7M / Sep 07, 2010
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others. $5.3M / Aug 03, 2009
Innolume has invented a novel comb laser light engine for short-reach optical interconnects between and within computers. Economical wavelength-division multiplexing (WDM) is enabled by this class of low-cost, low-power Fabry-Perot lasers. WDM, familiar from telecom, provides an efficient alternative to multiple lasers and underutilized parallelfiber/waveguides, reducing short-reach system cost and power. $9.4M / Series C / Aug 04, 2008
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others. Aug 01, 2008
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others. $1.1M / Jan 15, 2008
SCIENION AG is a life science company well positioned in the markets of ultra-low volume liquid handling systems and microarray technologies. They provide their customers with an integrated product portfolio facilitating and improving multiparallel bioanalytics, high throughput screening and high throughput production of microarrays in the genomicsand proteomics fields – from early research to manufacturing. $4.9M / Jul 18, 2006
Innolume has invented a novel comb laser light engine for short-reach optical interconnects between and within computers. Economical wavelength-division multiplexing (WDM) is enabled by this class of low-cost, low-power Fabry-Perot lasers. WDM, familiar from telecom, provides an efficient alternative to multiple lasers and underutilized parallelfiber/waveguides, reducing short-reach system cost and power. $9M / Series B / Jun 15, 2006
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others. $3.6M / Series B / May 08, 2006
COMCO AG COMCO AG
The COMCO security system detects and suppresses internal attacks on corporate networks that previously went undetected, as appropriate protections were not available. Series A / Jul 12, 2005

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Construction
Mobile
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Real Estate
Publishing
Wine and Spirits
Sporting Goods
Mobile Apps
Finance
Manufacturing
Music
FinTech
Social Media
Franchise
Internet
Art
Mobile Advertising
Android
Enterprise
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Sudan
Norway
Malawi
Isle of Man
Haiti
Iran
Madagascar
Lesotho
Nepal
Russian Federation
Pakistan
Turkey
Liberia
Mexico
Tajikistan
Romania
Sweden
Zambia
Oman
Poland
Puerto Rico
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Côte d'Ivoire
Kuwait
Czech Republic
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
New Zealand
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Botswana
Seychelles
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Sierra Leone
Philippines
El Salvador
Portugal
Senegal
India
Canada
Germany
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
United States
Tanzania
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Bangladesh
Cyprus
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does S-Venture Capital Dortmund invest in?

S-Venture Capital Dortmund invests primarily in Biotechnology, Guides and Genetics startups, most often at Series B and Funding Round stage. Most of the 9 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does S-Venture Capital Dortmund invest in?

S-Venture Capital Dortmund typically joins rounds of $3.6M–$9M at Series B. These are whole funding-round sizes, not S-Venture Capital Dortmund's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds S-Venture Capital Dortmund took part in.

How do I contact S-Venture Capital Dortmund?

Public channels for S-Venture Capital Dortmund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at S-Venture Capital Dortmund?

The team at S-Venture Capital Dortmund includes Bernd Meyer (CEO) and Gerhard Steinkamp (Director). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
S-Venture Capital Dortmund S-Venture Capital Dortmund Find emails